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Effect of Changes in Antibiotic Prescribing
on Patient Outcomes in a Community
Setting: A Natural Experiment in Australia
Justin Beilby, John Marley, Don Walker, Nicole Chamberlain, and Michelle Burke for the FIESTA Study Groupa
Department of General Practice, University of Adelaide, North Tce, Adelaide, Australia
This study examined whether a significant change in antibiotic use caused by an Australian government
directive targeted at amoxicillin with clavulanic acid (AC) was associated with changes in prescription share,
health care costs, and patient outcomes. We used an integrated database of computerized general practice
medical records, which included data regarding 34,242 patients and 318,234 recorded patient visits. There
were 15,303 antibiotic prescriptions provided to 9921 patients during a 4-year period, with AC prescribed for
1453 (14.6%) of these patients. A total of 5125 patient outcomes were identified. There was a shift away from
best-practice antibiotic prescribing, and a significant association was identified between the rate and cost of
process-of-care and patient outcomes and the decrease in AC-prescription share. This policy initiative created
unintended changes in prescribing behavior, increased costs to the government, and a trend toward poorer
patient outcomes. Detailed analyses are required before instigating initiatives aimed at changing clinicians’
prescribing behavior.
There have been few published studies to have exam-
ined the interaction between antibiotic prescribing and
patient outcomes, particularly from a community per-
spective. A small number of studies have attempted to
define appropriate therapy in terms of patient out-
comes, but those studies have been limited to hospitals
[1–3]. In contrast, the majority of antibiotics are pre-
scribed in outpatient and community practices. This
study examines complete longitudinal computerized
clinical records from 4 Australian general practices in-
volving 22 general practitioners (GPs) from July 1994
through June 1998.
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During this period, a significant change in the pre-
scribing of antibiotics in Australia occurred. This
change was prompted by a letter sent in February–
March 1996 by the Commonwealth Government’s
Health Insurance Commission (HIC), which subsidizes
medication use, to the top 2000 prescribers of amox-
icillin with clavulanic acid (AC). The letter contained
a number of statements, including the following com-
ments: AC should be used only to manage infections
in which resistance to amoxicillin is suspected or
proven; that hepatic problems could be complications
from the use of AC, particularly in elderly recipients;
and that there would be a follow-up audit, aimed at
GPs, to assess compliance with the recommendation
(HIC; Canberra, Australia; unpublished letter). No rec-
ommendation was provided regarding which antibiotic
to use in place of AC. The message contained within
this letter was widely disseminated in the medical press
and pharmaceutic marketing literature, so that the
change in prescribing was not limited to those who
directly received a letter. As a result, there was a sig-
nificant decrease in the national number of prescrip-
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tions for AC, with an increase in the prescription of other
antibiotics (as recorded by the Commonwealth Government
Drug Utilisation Subcommittee). There was a particular in-
crease in the prescribing of macrolides and, to a lesser extent,
the cephalosporins (P. McManus, personal communication).
Streptococcus pneumoniae is the principal causative agent for
sinusitis, otitis media (OM), and lower respiratory infection,
and the most recent Australian study to have analyzed isolates
obtained from multiple centers documented the following rates
of resistance in 1997 [4]: for AC and amoxicillin, 0.1% of
isolates were resistant and 0.2% had intermediate resistance;
for cefaclor, the rates were 4.0% and 17.4%, respectively; for
erythromycin, 15.6% and 0.7%, respectively; for tetracyclines,
15.7% and 0.2%, respectively; for cotrimoxazole, 33.4% and
12.4%, respectively.
On the basis of these resistance patterns, it seemed logical to
assess whether the therapeutic shift to cefaclor and the macrolides
produced poorer patient outcomes. The hypothesis was that the
targeted change in AC-prescribing behavior was associated with
changes in the number and rates of patient outcomes and pro-
cess-of-care outcomes. A time-series design [5, 6] was used to
identify the temporal relationship between the effect of the Com-
monwealth Government letter on prescription share and patient
outcomes. Inherent in the use of time series alone is the possibility
of ecologic bias [7]—that is, implying causal relationships from
associations between grouped data. To clarify whether ecologic
bias was present, individual patient-level data were examined,
adjusting for the antibiotic prescribed, patient age, and case mix.
METHODS
Creation and analysis of the overall database. The study
database consisted of computerized records from 4 general
practices based in 3 states in Australia. Of the 22 GPs who
contributed information to the study database, 10 (45%) were
aged !44 years, 13 (59%) were men, and 12 (55%) were in
full-time practice. Four (18%) of the 22 GPs remembered hav-
ing received the actual letter from the HIC.
The database contained information about 34,242 patients
who had generated 318,234 recorded patient visits. The visit
notes included encounter information, pathologic and diag-
nostic-imaging reports, and clinical summary and allergy data.
The participating GPs used free text to enter all consultation
information, and the pathologic and diagnostic information
was scanned into the notes. The fields in the notes did not
change throughout the complete study period; the GPs had
been using this method to collect this information for 110 years.
The following 4 specific study conditions, which are commonly
treated in general practice [8, 9], were chosen to answer the
study hypothesis: OM; acute sinusitis; and lower respiratory
tract infection, including bronchitis and pneumonia (LRTI) and
acute exacerbation of chronic bronchitis (AECB). Acute OM
and OM with effusion were considered together.
We used complex searches to identify all patient visits that
involved the conditions of interest. To do this, the database was
enhanced by the development of a full data dictionary of key
terms, which enabled comprehensive searching. These key
terms included all possible phrases that could identify mentions
of drugs, problems, and conditions. These visits were then sep-
arated from the database and individually checked. To achieve
this, trained data-entry staff read each note of interest and
mapped its relevant concepts to a controlled vocabulary of
terms that included diagnoses, tests, radiology, drugs, and ap-
propriate patient characteristics. All patient-identifying material
had been removed before this checking process began. The
intra- and interreliability of the data-entry staff, as measured
by k [10], was 10.85 for both.
Completeness of the database. External validation for com-
pleteness of the database included comparison of the consultation
numbers for the study database with those held by the HIC for
the period of 1994–1997. In Australia, the HIC has all recorded
information regarding community consultation for GPs.
Age and sex profile in the patient database. To assess the
representativeness of the patients to the Australian population,
the age and sex profiles of the database patient sample were
compared with the national Australian general practice attend-
ees [11] for the middle year of the study, 1997.
Patient numbers and case-mix profile. Patient numbers
were added together for each antibiotic both before and after
the letter was distributed. The total patient numbers and case
mix for each antibiotic were compared before and after the
letter. The case-mix profile was compared by means of a 12-
category classification system developed by Weiner et al. [12].
Differences in the time periods before and after the letter are
accounted for by using rates of episode of care (EOC; see the
“EOC” subsection below) [13].
Antibiotic use according to prescription share. Patterns
of antibiotic use for the study GPs were examined by means
of prescription shares. “Prescription share” refers to the per-
centage of the antibiotic ordered when compared with other
antibiotics in connection with an episode of sinusitis, OM,
LRTI, or AECB. The study prescription shares for AC and other
antibiotics were compared with the national antibiotic pre-
scription shares to ensure that the database changes corre-
sponded with national trends (P. McManus, personal com-
munication). Prescription share was the preferred measure of
antibiotic prescribing because it accounted for seasonal varia-
tion. Changes in prescription shares were reviewed against
changes in total use of antibiotics during the same period to
ensure prescription share changes were not driven by an in-
crease or decrease in antibiotic use.
Outcomes were separated into “patient outcomes” and “pro-
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cess-of-care outcomes” within an episode of sinusitis, OM,
LRTI, or AECB. The patient outcomes included uninitiated
return visits to the GP within 2 weeks of receiving the antibiotic,
hospitalization, and referral to a specialist. The process-of-care
measures included the following: CT scan of sinus and chest,
chest radiography, any pathology tests (e.g., complete blood
picture, sputum, erythrocyte sedimentation rate), and spiro-
metry, bronchoscopy, and sinoscopy.
Initially, all outcomes were collectively analyzed by simple sum
of events divided by the total number of GP encounters. Costs
were then attached to each outcome; then, outcomes were an-
alyzed by weighting each type of event by median cost; finally,
they were summed and divided by the total number of GP en-
counters. Median costs were taken from the national HIC sched-
ule [14] for pathologic and diagnostic-imaging services and the
tertiary-hospital case-mix table (P. Widdas, personal commu-
nication). The values (in Australian dollars) used in the weighted
analysis for patient outcomes were $56 for referral to a specialist,
$21.30 for return visits, and $2095 for hospitalizations; for pro-
cess measures, costs (in Australian dollars) were $16 for a pa-
thology test, $133 for radiology, and $115 for all other tests.
EOC. The data were defined by EOC, which describes the
period surrounding all care related to a specific clinical problem
presented [13]. A new EOC for a condition was begun if there
had been a month between visits for the same problem. There-
fore, an outcome was considered to be related to a specific
antibiotic if it occurred within the EOC in which the antibiotic
was prescribed.
Statistical analysis. For the intervention time point, seg-
mented regression lines were fitted to the time-series data to
determine where the significant changes occurred in both study
and national prescription share (P. Widdas, personal commu-
nication) [15]. All main antibiotic groups were examined. Both
1- and 2-breakpoint models were tried. For models with 2 break-
points, it was assumed that there existed 3 distinct and separate
linear relationships over time separated by 2 time points. The
residual sum of squares for each combination of breakpoints
during the length of the time series was examined, and the time
points at which this quantity was minimized were chosen [15,
16]. To test whether a change had occurred in the series and
whether the 3-segment regression may have been a better rep-
resentation of the data than was the simple linear regression and
2-segment regression, a likelihood ratio test was performed.
Splines [17] were used to define, in greater detail, the change in
AC and all antibiotics prescription share across the study data-
base. All analyses were completed by use of SAS/ETS, version
6.0 (SAS Institute) [18].
For time-series analyses, we used intervention analysis to de-
termine the effect of the letter on the level of the AC-prescription
share and outcome series [19, 20]. Autoregressive integrated
moving average (ARIMA) models were used to model the noise
in the series. In all cases, the form of the intervention was a step
shift. A step intervention was used to determine whether the
letter changed the level of the series in all months after the event.
The effect of the intervention was investigated for all antibiotic
prescriptions, antibiotic prescription share, sum of all patient and
process outcomes, and sum of patient and process-of-care out-
comes weighted by median costs. Rates of outcomes were cal-
culated as (1) sum of all patient and process outcomes divided
by total number of notes for indicator conditions (i.e., sinusitis,
OM, LRTI, AECB), and (2) sum of patient and process-of-care
outcomes weighted by median costs divided by total number of
notes for indicator conditions. The relationships between the
outcome series (rate and sum) and antibiotic prescription shares
were determined by use of a distributed lag transfer function
model. The effect of antibiotic prescribing was modeled such
that the impact on the outcome time series was distributed over
past lags (months) of antibiotic prescribing. This type of model
describes the level of outcomes as a linear function of the current
level of AC-prescription share and of the previous 3 months.
This is sensible for the conditions of interest; in particular, the
outcomes of interest are indicators of treatment failure, which
will not present at the time of the prescription, but, rather, at
some time after the treatment has begun.
For detailed analyses of EOC, EOCs were examined to de-
termine the antibiotic prescribed in the first instance and the
relationship with outcomes. Patient outcomes were measured
on the first visit and on any subsequent visit within 2 weeks
of the prescription for a new and active condition. The fre-
quency of patient and process-of-care outcomes that occurred
on the first visit were compared between the periods before
and after the letter for all antibiotics and for each antibiotic
separately. Comparisons were also made between the periods
before and after the letter in the proportion of EOCs with an
outcome after the first visit.
Multivariate regression models. These models were used
to ascertain the affect of the intervention on outcomes for each
antibiotic. Adjustments were made for the possible confound-
ing effects of condition, patient age, and case mix on patient
outcomes. Analyses were completed by use of SAS/ETS, version
6.0 (SAS Institute), and SCA (Scientific Computing Associates)
[21]. Ethical approval was obtained from the Adelaide Uni-
versity Institutional Ethics committee.
RESULTS
Completeness of the database. Abstracted data from the da-
tabase were consistent with national consultation claims data
from the HIC. In the study, there were ∼332,288 consultations
recorded within the database and 317,819 identified by the HIC.
This gives an agreement between the study database and the
HIC of 104%, implying that the study database completely
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Table 1. Comparison of profile of national gen-








Male Female Male Female
0–4 3.9 3.6 4.7 4.3
5–14 6.9 6.5 7.0 6.7
15–24 6.6 7.3 6.3 8.4
25–44 13.9 16.3 14.6 17.9
45–64 10.3 10.9 9.8 9.9
65–74 3.7 4.1 3.1 3.4
75 2.3 3.7 1.7 2.2
Total 47.5 52.5 47.2 52.8








Patients who received an
antibiotic prescription,c no. (%)
AC 738 (39) 810 (28)
Amoxicillin 1284 (68) 1521 (52)
Macrolidesd 765 (40) 1511 (52)
Cefaclor 1141 (60) 1866 (64)
Cephalexin 376 (20) 600 (21)
Tetracyclines 647 (34) 1050 (36)
Trimethoprim-sulfamethoxazole 107 (6) 114 (4)
Antibiotic prescriptions,e no. (%)
AC 860 (45) 986 (34)
Amoxicillin 1543 (81) 1782 (61)
Macrolidesd 882 (46) 1857 (55)
Cefaclor 1480 (78) 2539 (88)
Cephalexin 431 (23) 687 (24)
Tetracyclines 758 (40) 1233 (43)
Trimethoprim-sulfamethoxazole 122 (6) 143 (5)
Total 6076 (320) 9227 (318)
Outcomes, no. (%)
All adverse outcomes 584 (30.7) 1289 (44.4)
Hospitalizations 27 (1.4) 99 (3.4)
Referrals 123 (6.5) 228 (7.9)
Radiology 250 (13.2) 544 (18.8)
Pathology 174 (9.2) 387 (13.3)
Other tests 10 (0.5) 31 (1.1)
Return visits 1270 (66.8) 1982 (68.3)







All other antibiotics, excluding AC 7.1 9.5
NOTE. AC, amoxicillin with clavulanic acid.
a Nineteen-month period.
b Twenty-nine–month period.
c The number of patients who had 1 prescription of each antibiotic.
Some patients are recorded twice because they received 11 type of anti-
biotic. Overall, 9921 people had 1 of the conditions during the study period,
with AC prescribed for 1453 people in this group.
d Roxithromycin and erythromycin.
e The number of prescriptions written for each antibiotic.
f Rate of adverse patient outcomes per 100 episodes of care with 1
type of antibiotic prescribed.
captured all information from the practices during the study
period.
Age and sex profiles of the patient database. The age and
sex profiles of the overall patient sample that visited the study
general practices are presented in table 1; they were found to
be similar to those reported by the national Australian general
practice attendees [11].
Description of patients, chosen conditions, and case mix.
The number of EOCs for the chosen conditions were as follows:
(1) For all specified problems, there were 11,378 EOCs. A total
of 1329 patients were treated with AC alone, and 9811 received
other antibiotics. Two hundred thirty-eight patients received a
mixture of AC and other antibiotics within the same EOC. (2)
For OM, there were 3826 EOCs. A total of 419 patients were
treated with AC alone, and 3313 received other antibiotics.
Ninety-four received a mixture of AC and other antibiotics. (3)
For sinusitis, there were 2841 EOCs. A total of 428 patients
were treated with AC alone, and 2354 received other antibiotics.
Fifty-nine received a mixture of AC and other antibiotics. (4)
For LRTI, there were 4962 EOCs. A total of 515 patients were
treated with AC alone, and 4324 received other antibiotics. One
hundred twenty-three received a mixture of AC and other an-
tibiotics. (5) For AECB, there were 189 EOCs. A total of 34
patients were treated with AC alone, and 150 received other
antibiotics. Five received a mixture of AC and other antibiotics.
No antibiotics were given for 157 cases of OM, 236 cases of
sinusitis, 416 cases of LRTI, and 108 cases of AECB. It is im-
portant to note that the EOC for both AC and other antibiotic
groups do not add to the sum of the overall specified problems
because there may have been EOCs for which 1 condition
existed.
The numbers of patients who were given AC at least once
were 738 (before the letter) and 810 (after the letter). The most
common choices of antibiotics in Australia were selected for
comparison. Additional patient numbers for the other antibi-
otics are summarized in table 2—for example, the numbers of
patients provided amoxicillin at least once were 1284 (before
the letter) and 1521 (after the letter); for cefaclor, the numbers
were 1141 (before the letter) and 1866 (after the letter). Overall,
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Table 3. Patient numbers for the case-mix categories before and after a letter regarding prescription of
amoxicillin with clavulanic acid (AC) was sent to general practitioners.
Case mix
No. (%) of patients









Acute major conditions 169 (26.9) 1033 (29) 218 (32.8) 1499 (28.3)a
Acute minor conditions 30 (4.8) 129 (3.6) 36 (5.4) 232 (4.4)
Conditions that are likely to recur 48 (7.6) 280 (7.8) 61 (9.2) 514 (9.7)
Asthma 107 (17.0) 587 (16.5) 128 (19.2) 871 (16.4)
Chronic unstable medical conditions 23 (3.7) 193 (5.4) 28 (4.2) 276 (5.2)
Chronic stable medical conditions 69 (11) 415 (11.6) 97 (14.6) 744 (14.1)
Chronic stable specialty conditions 22 (3.5) 149 (4.2) 28 (4.2) 218 (4.1)
Eye or dental conditions — 1 (0.03) — 2 (0.0)
Chronic unstable specialty conditions — 3 (0.1) — 5 (0.1)
Psychological or psychophysiological conditions 25 (4) 46 (1.3) 43 (6.5) 304 (5.7)
Preventive or administrative — — — —
Pregnancy 6 (1) 36 (1) 6 (1) 53 (1)
All patients 629 3568 665 5295
NOTE. “All patients” indicates patients with 1 episode of care (EOC) that involved the specified antibiotic. Individual
patients may be counted more than once if they were identified as having 11 case mix. The percentage values are calculated
as all patients of given a specific antibiotic (e.g., AC with an acute major condition within an EOC divided by all patients given
the specified antibiotic—in this case, AC). It is important to note that the percentages do not add to 100 because there were
patients who received a specified antibiotic but who were without a case-mix category. The patient numbers are taken from
the EOCs in which there was either an AC prescription or a prescription of 1 other antibiotic alone.
a .P ! .05
9921 persons had 1 of the conditions during the study period,
and AC was prescribed for 1453 persons in this group.
Before the letter, the case-mix profiles of the patients who
had 1 of the specified conditions and who received AC alone
did not significantly differ from those of patients who received
other antibiotics ( ). In contrast, after the letter, thePp .237
case-mix profile of the patients who received AC was signifi-
cantly different from that of the patients who received other
antibiotics. After the letter, there was a significant case-mix
difference: 218 (32.8%) of the 665 patients who received AC
were identified as having acute major conditions, and 1499
(28.3%) of the 5295 patients who received other antibiotics
were identified with this case mix ( ; table 3).Pp .0164
Antibiotic use, including prescription shares. The total
amount of antibiotic prescribing remained relatively stableduring
the study period, both before the letter (319 prescriptions per
month; 19 months from June 1994–January 1996, with 6076
total prescriptions; table 2) and after the letter (318 prescriptions
per month; 29 months, with 9227 total prescriptions).
The study prescription shares for all antibiotics were sum-
marized by use of splines (figure 1). The decrease in AC- and
amoxicillin-prescription shares appears to be mirrored by an
increase in cephalosporin- and macrolide-prescription shares.
Segmented regression analyses for all antibiotics revealed 2 sig-
nificant intervention time points for the AC-prescription share
series. These were identified in May 1996 and August 1997. The
AC-prescription share was stable in the years preceding the in-
tervention and was estimated to be 13.8%. During the year of
the intervention, the AC-prescription share decreased and then
stabilized at 8.6%. The amoxicillin-prescription share showed a
steady decrease from 1994 until early 1997, with no excess de-
crease in the amoxicillin-prescription share at the time of the
intervention. The cephalosporin- and macrolide-prescription
shares showed steady increase during the study period. Closer
examination of specific prescribing rates (table 2) reveals further
evidence that macrolides and cefaclor were substituted for amox-
icillin and AC—that is, the rate of prescription ordering per
month for the macrolides before the letter was 46, and after the
letter, it was 66 prescriptions per month; for cefaclor, the figures
were 78 and 91, respectively; for amoxicillin, 81 and 64, respec-
tively; and for AC, 45 and 35, respectively. Time-series analysis
that used an intervention model with a prespecified breakpoint
at January 1996 indicated that the AC market share was stable
between July 1994 and December 1995, but the share dropped
∼0.2% per month between January 1996 and June 1998 (Pp
)..029
When all specific conditions are separately examined, AC-
prescription share changed significantly for sinusitis alone and
not for the other conditions.
Patient and process outcomes. The total number of out-
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Figure 1. The prescription share for amoxicillin with clavulanic acid (A/C) compared with the prescription shares for all antibiotics for the 4 general
practices involved (June 1994–July 1998). “Prescription share” refers to the prescribing percentage of an antibiotic as part of all antibiotics prescribing
among the study of general practitioners. The splines technique was used to smooth the prescription share lines. The cephalosporins include cefaclor
and cephalexin. AMOXYL, amoxicillin; HIC, Health Insurance Commission; Jan, January; Jul, July; TRIM&SULF, trimethoprim-sulfamethoxazole.
comes were 5125, comprising 126 hospitalizations, 351 refer-
rals, 3252 return visits, 794 radiologic investigations, 561 pa-
thology tests, and 41 other investigations (which included
spirometry, bronchoscopy, and sinoscopy). There were 1854
adverse outcomes in the period before the letter and 3271 in
the period after the letter (table 2).
When the rate of patient and process-of-care outcomes per
100 EOCs was calculated before and after the letter, it was found
that the rate for amoxicillin remained the same, at 3.8. For
macrolides, the rate changed from 9.3 to 11.5; for cefaclor, 6.9
to 7.1; for cephalexin, 9.0 to 9.6; and for AC, 7.9 to 11.3. Overall,
for all antibiotics (excluding AC), the mean rates were 7.1
before the letter and 9.5 after the letter (table 2).
Before the letter, there was a single EOC in which AC was
prescribed and a hospitalization was reported. After the letter,
there were 14 EOCs in which AC was prescribed and a hospi-
talization was reported. Of all EOCs that involved AC before the
letter, 0.14 per 100 EOCs had a hospitalization, whereas of all
EOCs that involved AC after the letter—1.84 per 100 EOCs—had
a hospitalization ( ). This was the only significant in-Pp .0011
crease after the letter for the EOC that involved AC. This suggests
that the GPs may have been prescribing AC to patients who had
more severe illness. Conversely, more patients after the letter may
have been exposed to AC-resistant bacteria or to such organisms
as Mycoplasma or Legionella species, for which AC is not the
appropriate antibiotic. The information regarding the causative
organisms was not available in the database. For the EOCs in
which the macrolides cefaclor, cephalexin, and amoxicillin were
given alone, there were no significant changes in the rate of each
outcome group. However, when we analyzed all EOCs for which
11 of these antibiotics were given as a total group, there were
significant increases in the rate of adverse outcomes per 100 other
antibiotic-related EOCs for the following: hospitalizations (0.44
before the letter and 0.86 after the letter; ), radiologicPp .0054
investigations (3.27 before the letter and 4.87 after the letter;
), and pathologic investigations (2.73 before the letterPp .00001
and 3.62 after the letter; ).Pp .005489
Time-series analysis of the relationship of the antibiotic-
prescription share and outcomes. Overall, there was a sig-
nificant association between the increase in the rate per month
for all outcomes and the decrease in AC-prescription share
( ), with a 3-month lag. There was also a significantPp .011
association between AC-prescription share and overall outcome
rate weighted by relative cost ( ; table 4). The rate ofPp .0024
outcomes per month from July 1994 to June 1998 is displayed
graphically in figures 2 and 3, in which it is further separated
into process-of-care outcomes and patient outcomes, with and
without return visits. The rate of patient outcomes, including
return visits, was not significantly associated with AC-prescrip-
tion share (table 4). However, when return visits were excluded,
there was a significant association ( ) and marginalPp .0365
association at the 3-month lag ( ). The rate of process-Pp .0689
of-care outcomes was significantly associated with AC-prescrip-
tion share also at the 3-month lag ( ). When the ratesPp .006
of patient outcomes with and without return visits series were
weighted by cost, there was a significant association with AC-
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Table 4. Intervention shift parameters for amoxicillin with clavulanic acid–prescription
share and overall patient and process-of-care outcome time series, including costs.
Variable Transfer function model Noise model P
P for
3-month lag
Rate of overall outcomes Distributed lag MA (2) — .011
Rate of overall outcome cost Simple linear regression White noise .0024 NS
Patient outcome rate
Including return visits Simple linear regression White noise NS —
Excluding return visits Simple linear regression White noise .0365 .0689
Process-of-care outcome rate Distributed lag AR (1) — .006
Patient outcome rate cost
Including return visits Simple linear regression White noise .0081 NS
Excluding return visits Simple linear regression White noise .0114 NS
Process-of-care rate cost Simple linear regression White noise — .0242
NOTE. AR (1), autoregressive model order 1; MA (2), moving average model order 2.
Figure 2. Rate of patient outcomes per 100 encounters. HIC, Health Insurance Commission; Jan, January; Jul, July.
prescription share ( and , respectively).Pp .0114 Pp .0081
There was a significant association between process-of-care out-
comes weighted by relative cost and AC-prescription share
( ) at the 3-month lag.Pp .0242
Detailed analysis of the EOCs. All EOCs that involved
new and active conditions were sought, and the antibiotic pre-
scribed at the first visit was determined. Occurrences of patient
or process-of-care outcomes within 2 weeks after the prescrip-
tion (but not on the day that the prescription was written)
were identified. Initially, the univariate model examined out-
comes after the first visit. There was no significant increase in
the proportion of EOCs with a patient outcome before and
after the letter ( ). There was a significant increase inPp .1776
the proportion of EOCs with a process-of-care outcome after
the letter ( ). When broken down according to anti-P ! .0001
biotic, there was a significant increase in the proportion of
EOCs in which tetracyclines were prescribed, and process-of-
care outcomes were analyzed after the letter, as compared with
before the letter ( )Pp .0304
EOCs in which patient outcomes occurred on the first visit
(during which an antibiotic was prescribed) were then exam-
ined. There was a significant increase in the proportion of EOCs
that involved a patient outcome before and after the letter (2.3%
before the letter and 6.1% after the letter; ). There wasP ! .0001
also a significant increase in the proportion of EOCs with a
process-of-care outcome after the letter (4.3% before the letter
and 10.2% after the letter; ). These trends are consis-P ! .0001
tent for all antibiotics.
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Figure 3. Rate of adverse patient outcomes (weighed by relative costs) per encounter. HIC, Health Insurance Commission; Jan, January; Jul, July.
Multivariate regression models. In the multivariate model,
which adjusts for age, sex, and case mix, EOCs in which an
antibiotic was prescribed were no more likely to have a patient
outcome after the first visit in the period after the letter than
they were in the period before the letter. Similarly, EOCs in
which an antibiotic was prescribed were no more likely to have
process-of-care outcomes after the first visit in the period after
the letter than they were during the period before the letter.
Overall, there was a significant increase in the number of
EOCs in which there were patient and process-of-care outcomes
identified on the initial visit in the period after the letter (com-
pared with the period before the letter: RR, 2.6; ; andP ! .0001
RR, 2.3; , respectively; table 5). EOCs in patients whoP ! .0001
were prescribed AC showed a significantly greater risk of a
patient outcome during the initial visit after the letter when
compared with the period before the letter (RR, 3.6; Pp
). EOCs in patients who were prescribed AC showed a.0025
significantly greater risk of a process-of-care outcome on the
initial visit in the period after the letter compared with the
period before the letter (RR, 2.26; ). This may againPp .0061
reflect the fact that the GPs were prescribing AC to patients
with more severe illness.
DISCUSSION
Before commenting on the results, it is important to examine
the validity of the findings. All chosen outcomes were sought
from the EOC (in which the conditions of interest were found)
by trained staff, and all used defined criteria. The GPs involved
in the study enter all of their data regarding patient medical
records into the computer, and they have been gathering infor-
mation in this manner for 110 years. As such, there was complete
capture of study data, including prescribing behavior and out-
comes [22]. Furthermore, the comparison with the HIC revealed
total coverage of all encounter data. Because the medical records
were obtained from well-established general practices, there is
no suggestion that selection bias or a change in patient behavior
could explain the study findings. Despite the fact that patients
were not formally linked to a specific GP in Australia, there is
evidence that patients are loyal to individual practices [23]. Fi-
nally, there is no information that, during the winters of 1996
and 1997, other situations, such as an influenza epidemic [24],
may have caused the increase in outcomes.
Individual and ecologic measures were integrated into the
study analyses because this is the best way to deal with the pos-
sibility of ecologic bias [7]. Within the study database, there was
no available information on bacterial resistance, and as such, it
was not possible to adjust for this confounding variable at the
individual level. An alternative explanation for the findings may
be that bacterial resistance had increased during this time. In
Australia, there is some evidence that this was occurring, with
the rates of penicillin-resistant Streptococcus pneumoniae increas-
ing from 1% of isolates in 1989, to 7% in 1994, and to 125%
in 1997 [4]. Although altered microbiology and bacterial resis-
tance could explain the overall increase in patient outcomes,
process-of-care outcomes would not have been influenced by
this variable.
In an examination of the relationship between prescription
shares, the monthly antibiotic prescribing rate before the let-
ter was similar to that after the letter. This provided evidence
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Table 5. The outcomes of multivariate regression analyses,
according to visit per episode of care.
Parameter RR P
























NOTE. RR is the risk of outcome after the letter divided by the risk
of an outcome before the letter, after adjusting for age, sex, and case mix.
An RR of 11 implies that the probability of an outcome is greater in the
period after intervention compared with the period before intervention.
AC, amoxicillin with clavulanic acid.
that the AC-prescription share did not decrease in the GP da-
tabase because of an increase in the prescribing volume. In the
time-series analyses, patient outcomes (excluding return visits)
showed a significant association ( ) with the decreasePp .0365
in AC-prescription share. In this study population, the main
patient outcomes in which increases have occurred are hospi-
talizations and referrals to specialists, but not uninitiated return
visits. The process-of-care outcomes were significantly
associated with AC-prescription share at the 3-month lag. De-
tailed examination of the EOCs revealed increases in process-of-
care outcomes and patient outcomes at the first visits for all
antibiotic groups. In the regression model that involved age, sex,
and case mix, all outcomes increased at the first visit, with a
trend to increases in process-of-care outcomes after the initial
visit. Clinically, the letter seems to have had a delayed effect on
the process-of-care outcomes.
The study examined information from 9921 patients of 22
GPs throughout Australia; the patients experienced 11,378 EOCs
for the conditions of interest. A total of 15,303 antibiotic pre-
scriptions were written during the 4-year study period, with a
total of 3729 patient outcomes and 1396 process-of-care out-
comes identified. The letter had a substantial effect on the pattern
of antibiotic use among these GPs. A cascade of events occurred.
There seems to have been a shift away from best-practice anti-
biotic prescribing (as outlined in the contemporary Australian
antibiotic guidelines) among these GPs. For example, for OM
and sinusitis, the guidelines available at that time recommend
amoxicillin as first-line therapy; AC is recommended as second-
line therapy for situations in which “poor response may suggest
infection with resistant organisms” [25]. The cephalosporins and
macrolides are not recommended first- or second-line therapy,
with the exception of cefaclor, which is provided to persons who
are allergic to penicillin.
There have been changes in management by the GPs in the
4 practices whose medical records were gathered. After the letter,
AC appeared to be used for sicker patients, some of whom re-
quired hospitalization. This was, in fact, one of the desired effects
of the letter. The GPs seemed to have ordered more investigations
after the letter, with a resultant increase in the cost to society.
The reason for this change is unclear, but after the distribution
of the letter, GPs seem to have shifted to a more conservative
model of practice.
The effect on patient outcomes is less clear, although some
trends are worth noting. Patient outcomes, particularly hospi-
talizations and referrals, did increase after the letter. Within the
time-series analyses, there was a significant association between
the increase in patient outcomes and the decrease in AC pre-
scriptions. Calculation of the rate of outcomes per EOC in which
macrolides, cefaclor, cephalexin, and amoxicillin were given re-
vealed an overall increase (before and after the letter) in the rates
of hospitalization. The rate of outcomes per EOC in which AC
was prescribed increased because the GPs seemed to be prescrib-
ing AC for sicker patients, many of whom ended up in the
hospital. Detailed analyses of the EOCs and the multivariate
analyses indicated that some of the increase in patient outcomes
was because sicker patients presented at the first visit—par-
ticularly patients who received AC and the tetracyclines.
Although the link between microbiologic in vitro resistance
and patient outcomes is uncertain [26], there is evidence that
both the morbidity and length and possibility of hospitalization
for persons infected with drug-susceptible organisms are double
those for persons infected with drug-resistant bacteria [27]. The
value of observational databases (such as the one used in this
study to document the link between antibiotic resistance and
patient outcomes) deserves more exploration, particularly when
it is known that very large sample sizes are required to document
differences in outcomes for these common infectious diseases
[28].
The study successfully measured the effectiveness of prescrib-
ing for common conditions among GPs during a time when a
policy-driven letter influenced GP behavior. The letter was sent
by a government agency and did not provide information re-
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garding drug-substitution choices [29]. Complex changes oc-
curred that seem to have resulted in more conservative GP be-
havior, increased cost to government, and a general trend toward
poorer patient outcomes. National policies aimed at changing
the prescribing behavior of GPs need to carefully analyze the
likely effect on clinicians, patients, and the health system before
being initiated.
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